Kezar Life Sciences Recognized as 2021 Bay Area Best Places to Work

·3 min read

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, has been recognized as a winner of the 2021 Bay Area Best Places to Work, an awards program presented by the San Francisco Business Times and the Silicon Valley Business Journal.

Select employers from the Bay Area were named winners of the award on May 7, 2021. These winning organizations were honored for having created exceptional workplaces that their employees value highly.

"Being recognized as a Best Place to Work in the Bay Area, particularly in a pandemic, is an honor and a testament to the company culture we work to cultivate at Kezar," said John Fowler, Chief Executive Officer, Kezar Life Sciences. "Our employees are the lifeblood of our company, and I am proud that their spirit of teamwork, creativity and positivity is being recognized with this award. I believe that our collaborative team spirit not only makes Kezar a great place to work but is the key factor supporting our mission to bring new medicines to patients in need."

Award applicants were evaluated and ranked across five categories according to the number of Bay Area employees. The ranking found companies in the region whose employees rate them as the highest on such values as fun, collaborative culture, solid compensation and benefits offerings and other amenities as well as management practices. The rankings were unveiled on in the San Francisco Business Times and the Silicon Valley Business Journal.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company bringing novel treatments to patients with rare autoimmune diseases and cancer. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. KZR-616, its lead development candidate, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis. Additionally, KZR-261, the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway, is undergoing IND-enabling activities. For more information, visit kezarlifesciences.com, and follow us on Twitter, Facebook, LinkedIn and YouTube.

About 2021 Bay Area Best Places to Work

Best Places to Work is an innovative publication and awards program produced by the San Francisco Business Times and the Silicon Valley Business Journal. The rankings were determined by surveys that went directly to employees who answered a series of questions. The survey was administered online by the employers and through a service provided by Quantum Workplace, our research partner. The rankings are numeric based on Quantum’s scoring process. By ranking companies and sharing best practices we facilitate idea sharing and help other companies learn from the best.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005826/en/

Contacts

Media Contact:
Celia Economides
SVP, Strategy & External Affairs
IR@kezarbio.com

Investor Contact:
Argot Partners
(212)-600-1902
kezar@argotpartners.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting